Full Text View
Tabular View
No Study Results Posted
Related Studies
Optimization of UV Radiation Therapy in Psoriasis
This study is currently recruiting participants.
Verified by Department of Veterans Affairs, February 2009
First Received: May 4, 2007   Last Updated: February 9, 2009   History of Changes
Sponsors and Collaborators: Department of Veterans Affairs
National Institutes of Health (NIH)
Department of Dermatology
Information provided by: Department of Veterans Affairs
ClinicalTrials.gov Identifier: NCT00470392
  Purpose

The purpose of this study is 1) to determine whether Imiquimod or Steroid pretreatment modifies UVB laser light response resulting in increased cell death compared to UVB laser light alone; 2) to determine if pretreatment of psoriatic lesions with Imiquimod or Steroid prior to UVB laser light exposure selectively effects various T cell functions; 3) to determine clinical results from the Imiquimod/Steroid/UVB laser light and correlate those changes with immuno-histochemical changes in the skin; and 4) to determine if single high dose lesion limited UVB laser light intervention combined with Imiquimod or Steroid influences T cell changes


Condition Intervention Phase
Psoriasis
Drug: Imiquimod
Drug: Clobetasol (glucosteroid)
Device: Excimer laser (UVB light) treatment
Phase IV

MedlinePlus related topics: Psoriasis Radiation Therapy
Drug Information available for: Clobetasol Clobetasol propionate S 26308
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Active Control, Crossover Assignment, Efficacy Study
Official Title: Mechanistically-Based Optimization of UV Radiation Therapy in Psoriasis

Further study details as provided by Department of Veterans Affairs:

Primary Outcome Measures:
  • T cell apoptosis [ Time Frame: Not relevant as biopsy specimens may be preserved until needed. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Lesional Psoriasis Area and Assessment [ Time Frame: Assessed via the Psoriasis Area and Severity Index at each study visit. ] [ Designated as safety issue: No ]

Estimated Enrollment: 50
Study Start Date: May 2007
Estimated Study Completion Date: May 2010
Estimated Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1 Drug: Imiquimod
Topical immiquimod will be applied twice daily for a period of 2 weeks to pre-identified psoriasis lesions. Time period of treatment is subject to change based on experiment results.
Drug: Clobetasol (glucosteroid)
Topical clobetasol will be applied twice daily for a period of 2 weeks to pre-identified psoriasis lesions. Time period of treatment is subject to change based on experiment results.
Device: Excimer laser (UVB light) treatment
Varying does of UVB excimer laser light, based upon patient MED and plaque thickness, will be applied after imiquimod and/or clobetasol treatment to pre-identified psoriasis lesions.

Detailed Description:

The characteristic lesion of psoriasis is a sharply demarcated erythematous papule or plaque with excessive scaling due to hyperproliferating keratinocytes, infiltrating granulocytes, and a dense mononuclear infiltrate with activated T cells. To date, no one mechanism has been explanatory for the panoply of changes that occur in both the dermis and epidermis of psoriasis patients. Several key findings have shown that cutaneous T cells play a key role in the propagation of the disease; memory-type T cells home to the skin, specifically due to expression of cutaneous lymphocyte antigen (CLA), and are the main effector cells in psoriatic tissue responsible for the production of cytokines that result in exacerbated cutaneous inflammation. T cell recruitment is thought to occur in psoriasis, in part,as a result of cytokine and chemokine release from keratinocytes, macrophages, and endothelial cells. CLA-positive T cells migrate into the tissues where memory-effector T cells are activated and expand. This migration is critical to maintenance of the psoriasis lesions, because anti-LFA-1 antibodies (efalizumab) are effective in treating psoriasis, resulting in blood lymphocytosis and tissue depletion of T cells. Despite many years of using UVB phototherapy in the treatment of psoriasis, its mechanism of action is based mainly on in vitro exposures of isolated cells and on extrapolations from UV effects on normal skin, with little direct data from lesional skin.

Previously, our studies determined optimal single efficacious dose using the Excimer laser, refined the mechanism of UVB action in psoriasis, developed key cytokine quantitative meth -ods to assess targeted mRNA levels in psoriatic tissue after treatment, demonstrated that regulatory T cells from psoriasis tissue and blood appear to have a functional defect,and demon- strated that UVA component of solar radiation is a critical and significant contributor to UV-induced in vivo immuno-suppression. All of these previous findings lead us to our current hypothesis that direct selective apoptotic effects on the T mem/Teff cells may result in decreased APC activation and IL-12 over-riding of Treg suppression and a re-balanced Tre:Tmem/eff cell ratio which in turn may have a sustained remittive effect (high duration multi-month clearing of a psoriasis lesion after a single UVB laser light treatment.)

  Eligibility

Ages Eligible for Study:   21 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • The presence of plaque-type psoriasis in areas of the trunk, buttock, or extremities that are amenable to biopsy and evaluable disease in at least 2 cm target treatment sites separated by 1 cm
  • Age 21-70, both genders, all ethnicities
  • No contraindications to phototherapy or biopsy procedures
  • No topical steroid, tar, phototherapy, Vitamin D, or retinoid therapy to target lesions for at least 2 weeks prior to the study
  • No systemic psoriasis therapy for at least four weeks prior to the study
  • Able to give informed consent under IRB approval procedures

Exclusion Criteria:

  • Photosensitivity disorders
  • Active untreated diseases or medication usage which may interfere with UVB, wound healing, or immune function
  • Hypersensitivity to both amide and esther anesthetics or epinephrine (keratome biopsies only)
  • Inability to withdraw from aspirin or other anti-clotting agents for at least one week prior to the biopsies (keratome biopsies only)
  • Inability to provide informed consent
  • Pregnancy and /or lactating
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00470392

Contacts
Contact: Benjamin R Bohaty, BS (513) 255-5436 brb64@case.edu
Contact: Laura J Beck-Wilson (216) 791-3800 ext 5845 Laura.Beck-Wilson@va.gov

Locations
United States, Ohio
VA Medical Center, Cleveland Recruiting
Cleveland, Ohio, United States, 44106
Contact: Benjamin R Bohaty, BS     513-255-5436     brb64@case.edu    
Principal Investigator: Kevin D Cooper, MD            
Sponsors and Collaborators
Department of Dermatology
Investigators
Principal Investigator: Kevin D Cooper, MD VA Medical Center, Cleveland
  More Information

Additional Information:
Publications:
Responsible Party: Department of Veterans Affairs ( Cooper, Kevin - Principal Investigator )
Study ID Numbers: IMMB-004-06S
Study First Received: May 4, 2007
Last Updated: February 9, 2009
ClinicalTrials.gov Identifier: NCT00470392     History of Changes
Health Authority: United States: Federal Government

Keywords provided by Department of Veterans Affairs:
Erythema
optimization
Papule
Plaque
pretreatment
T cells
UVB laser light

Study placed in the following topic categories:
Anti-Inflammatory Agents
Erythema
Skin Diseases
Immunologic Factors
Hormone Antagonists
Interferons
Adjuvants, Immunologic
Hormones, Hormone Substitutes, and Hormone Antagonists
Imiquimod
Glucocorticoids
Hormones
Clobetasol
Psoriasis
Skin Diseases, Papulosquamous

Additional relevant MeSH terms:
Anti-Inflammatory Agents
Interferon Inducers
Immunologic Factors
Skin Diseases
Antineoplastic Agents
Physiological Effects of Drugs
Adjuvants, Immunologic
Hormones, Hormone Substitutes, and Hormone Antagonists
Imiquimod
Glucocorticoids
Hormones
Pharmacologic Actions
Clobetasol
Psoriasis
Therapeutic Uses
Skin Diseases, Papulosquamous

ClinicalTrials.gov processed this record on May 07, 2009